Stem Cell Differentiation and Cytogenetics Group, Biophysics Department, GSI Helmholtz Center for Heavy Ion Research, Darmstadt, Germany.
Methods Mol Biol. 2021;2269:25-33. doi: 10.1007/978-1-0716-1225-5_2.
In an increasingly geriatric population, in which elderly people frequently face chronic diseases and degenerative conditions, cell therapies as part of novel regenerative medicine approaches are of great interest. Even though today's cell therapies mostly rely on adult stem cells like the mesenchymal stem cells or primary somatic cells, pluripotent stem cells represent an enormously versatile cell model to explore possible new avenues in the field of regenerative medicine due to their capacity to grow indefinitely and to differentiate into the desired cell types. The discovery of reprogramming somatic cells into induced pluripotent stem cells augmented the pool of applicable cell entities so that researchers nowadays can resort to embryonic stem cells, but also to a plethora of patient- and disease-specific induced pluripotent stem cells. The ease of targeted genome engineering is an additional benefit that allows using pluripotent stem cells for disease modeling, drug discovery, and the development of cell therapies. However, the task is still demanding as the generation of subpopulations and a sufficient cell maturation for some cell entities have yet to be achieved. Likewise, even though for some applications the cells of interest can be produced in the large-scale dimensions and purity that are required for clinical purposes, proper integration, and function in the host tissue remain challenging. Nonetheless, the immense progress that has been made over the last decades warrants the prominent role of pluripotent stem cells in regenerative medicine as in vitro models to broaden our knowledge of disease onset/progression and treatment as well as in vivo as a substitution of damaged/aged tissue.
在人口老龄化日益加剧的情况下,老年人经常面临慢性疾病和退行性疾病,因此细胞疗法作为新型再生医学方法的一部分引起了极大的兴趣。尽管当今的细胞疗法主要依赖于间充质干细胞或原代体细胞等成人干细胞,但多能干细胞因其无限增殖和分化为所需细胞类型的能力,成为探索再生医学领域新途径的极具多功能性的细胞模型。体细胞重编程为诱导多能干细胞的发现增加了适用细胞实体的数量,因此研究人员现在可以利用胚胎干细胞,也可以利用大量患者特异性和疾病特异性诱导多能干细胞。靶向基因组工程的易于操作是另一个好处,它允许使用多能干细胞进行疾病建模、药物发现和细胞疗法的开发。然而,这项任务仍然具有挑战性,因为一些细胞实体的亚群产生和充分的细胞成熟尚未实现。同样,尽管对于某些应用,有兴趣的细胞可以在临床所需的大规模和纯度下生产,但在宿主组织中的适当整合和功能仍然具有挑战性。尽管如此,过去几十年所取得的巨大进展证明了多能干细胞在再生医学中的突出作用,既是体外模型,可拓宽我们对疾病发生/进展和治疗的认识,也是体内替代受损/衰老组织的模型。